// App-Quantinova.ai

OP0050 : ADALIMUMAB INTRODUCTION VERSUS METHOTREXATE DOSE ESCALATION IN PATIENTS WITH INADEQUATELY CONTROLLED PSORIATIC ARTHRITIS: RESULTS FROM RANDOMIZED PHASE 4 CONTROL STUDY

Researchers

Presenter

  • L. C. Coates

Principal Investigators

  • W. Tillett

  • M. A. Dagostino

  • P. Rahman

  • F. Behrens

  • P. G. Conaghan

  • E. Mcdearmon-Blondell

  • X. Bu

  • L. Chen

  • M. Kapoor

  • P. J. Mease

Medical Centers

  • University of Oxford, Oxford, United Kingdom

  • University of Bath, Bath, United Kingdom

  • Paris-Saclay Versailles University, Hôpital Ambroise Paré, Boulogne-Billancourt, France

  • Memorial University, St. John's, NF, Canada

  • Goethe University & Fraunhofer IME-TMP and CIMD, Frankfurt, Germany

  • University of Leeds, Leeds, United Kingdom

  • Swedish Medical Center/Providence St. Joseph Health, Seattle, United States of America

Locations

  • United Kingdom

  • France

  • Canada

  • Germany

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Dermatology

  • Musculoskeletal

  • Autoimmune (AI)

Disease

  • Psoriatic arthritis

  • Psoriasis

Biomarkers

  • Malondialdehyde

Drug/Treatment

  • Methotrexate

  • Adalimumab

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

  • Controlled

  • Dose Escalation

Phase

  • IV

Study Id's

  • N/A

Sponsors

  • Abbvie

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved